Search Results
You are looking at 1 - 2 of 2 items for
- Author: M Bai x
- Refine by access: All content x
Search for other papers by RA Bradbury in
Google Scholar
PubMed
Search for other papers by KL Sunn in
Google Scholar
PubMed
Search for other papers by M Crossley in
Google Scholar
PubMed
Search for other papers by M Bai in
Google Scholar
PubMed
Search for other papers by EM Brown in
Google Scholar
PubMed
Search for other papers by L Delbridge in
Google Scholar
PubMed
Search for other papers by AD Conigrave in
Google Scholar
PubMed
Fura-2-loaded human cytotrophoblasts responded to elevated extracellular Ca2+ concentration ([Ca2+]o) with monophasic or, in the case of large (> 20 microns) extravillous cells, biphasic elevations in intracellular free Ca2+ ion concentration ([Ca2+]i) that returned to baseline levels after restoration of control [Ca2+]o. Large extravillous cytotrophoblasts also responded to elevated [Mg2+]o with transient elevations in [Ca2+]i, consistent with the behaviour of the parathyroid Ca2(+)-sensing receptor. Expression of the parathyroid Ca2(+)-sensing receptor in placental cells was confirmed using Northern blot and reverse transcription (RT)-PCR analysis. However, the major transcript in human placental cells (6.2 kb) differed from that expressed by human parathyroid cells (5.6 kb). RT-PCR analysis and DNA sequencing of key PCR products also revealed the presence of a splice variant in placental and parathyroid cells that lacks exon 3.
Search for other papers by M Alexandra Sorocéanu in
Google Scholar
PubMed
Search for other papers by Dengshun Miao in
Google Scholar
PubMed
Search for other papers by Xiu-Ying Bai in
Google Scholar
PubMed
Search for other papers by Hanyi Su in
Google Scholar
PubMed
Search for other papers by David Goltzman in
Google Scholar
PubMed
Search for other papers by Andrew C Karaplis in
Google Scholar
PubMed
Thiazolidinediones (TZDs) increase peripheral tissue insulin sensitivity in patients with type 2 diabetes mellitus by activating the nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ). In bone marrow stromal cell cultures and in vivo, activation of PPARγ by high doses (20 mg/kg/day) of TZDs has been reported to alter stem cell differentiation by promoting commitment of progenitor cells to the adipocytic lineage while inhibiting osteoblastogenesis. Here, we have examined the in vivo effects of low-dose rosiglitazone (3 mg/kg/day) on bone, administered to mice by gavage for 90 days. Rosiglitazone-treated mice had increased weight when compared with controls, with no significant alterations in serum levels of glucose, calcium or parathyroid hormone (PTH). Bone mineral density (BMD) at the lumbar vertebrae (L1–L4), ilium/sacrum, and total body was diminished by rosiglitazone treatment. Histologically, bone was characterized by decreased trabecular bone volume and increased marrow space with no significant change in bone marrow adipocity. Decreased osteoblast number and activity due to increased apoptotic death of osteoblasts and osteocytes was apparent while osteoclast parameters and serum levels of osteocalcin, alkaline phosphatase activity, and leptin were unaltered by rosiglitazone treatment. Therefore, the imbalance in bone remodeling that follows rosiglitazone administration arises from increased apoptotic death of osteogenic cells and diminished bone formation leading to the observed decrease in trabecular bone volume and BMD. These novel in vivo effects of TZDs on bone are of clinical relevance as patients with type 2 diabetes mellitus and other insulin resistant states treated with these agents may potentially be at increased risk of osteoporosis.
